Guosen Securities (HK)  
Skip Navigation Links

()
分析师 建议 目标股价 上升/下降(%)
总市值(十亿/十亿美元) 日均成交额(百万美元) 收盘 52周最高/最低()
/ -
+ 财务摘要 点击图标下载Excel版本
 
- 损益表 点击图标下载Excel版本
 
- 资产负债表 点击图标下载Excel版本
 
- 财务比率 点击图标下载Excel版本
 
- 杜邦分析 点击图标下载Excel版本
 
- 现金流 点击图标下载Excel版本
 
股票数据
 一天一周一个月三个月六个月一年从月初从年初
绝对回报 (%) 3.95 7.99 (4.94) (20.89) (22.72) 13.12 (6.02) 20.19
绝对回报 (美元, %) 3.94 7.93 (4.88) (20.78) (22.63) 12.57 (6.15) 19.80
相对于 HSI 回报 (%) 3.53 8.92 1.79 (12.14) (5.96) 22.35 2.00 34.76
 
最新五个研究报告
下面包含5个最新的研究报告,请到研究报告存库页面检索所有相关文件。
 
中国中药 (570 HK) 配方颗粒销售的好势头持续 - 8月 25, 2018 (8 页)  
8月14日收市后,中国中药公布其上半年盈利为人民币7.6亿元(同比增长23.6%),占我们全年的18财年预测的51.6%,而市场预期为52.1%(17上半年:51.8%)。18上半年,配方颗粒销售额同比增长37%,超过我们18全年的23%(17上半年:24%)。在分析师会议后,我们将18全年的配方颗粒销售额从同比增速的23%提高至31%。尽管配方颗粒和中药饮片销售额预测提高,因人民币贬值,我们微降目标价至8.05港元。维持买入评级。

China TCM (570 HK) No doubt about growth momentum - 5月 9, 2018 (7 页)  
Being the market leader and pioneer of Chinese medicine formula granule (CCMG), we believe China TCM’s active sales/marketing coverage and smart dispensing machines will keep its CCMG sales over 21% y-o-y growth in 2018F-19F. Expanding its decoction pieces’ production capacity helps lift its y-o-y total revenue to 22%/21%/19% in FY18F-20F from 17%/16%/14%. Keep BUY with higher SOTP-TP at HKD8.50 on bigger CCMG and decoction pieces sales.

China TCM (570 HK) Growth stays sustainable - 4月 3, 2018 (9 页)  
China TCM, on 28 Mar, released its FY17 net profit at RMB1.2bn, while core profit of RMB1,187m (+26% y-o-y) was consistent with ours and Bloomberg consensus. Post analyst meeting, in 2018F-19F, we keep our y-o-y sales growth from (1) finished drug at 10%/12%; and (2) concentrated TCM granules (CCMG) at 19%/17% on more partnerships with peers, hospital coverage and smart dispensing machines to serve more patients. Keep BUY with higher SOTP-TP of HKD6.80 on bigger valuation of its finished drugs & CCMG leadership.

China Healthcare Focus on biotech and high-end drugmakers - 3月 14, 2018 (18 页)  
In the upcoming (Dec-ended) result season and from those stocks we actively cover, we expect biotech (Genscript) and high-end drugmakers (3SBio and Livzon Pharm) to have in-line results with Bloomberg consensus and ours. Moreover, concentrated Chinese medicine granule (CCMG) leader (China TCM) is forecast to beat consensus, on recovering finished drug and stable CCMG sales and margins. We see drug-makers like United Lab, Luye and Sinopharm as the key distributor would likely fall short of consensus estimate.

China TCM (570 HK) Future outlook stays bright - 8月 22, 2017 (9 页)  
China TCM, on 20 Aug, released its 1H17 result with core profit of RMB615m (+26% y-o-y), 10% beat ours and consensus. Post analyst meeting, in 2017-19, we keep our y-o-y sales growth from (1) finished drug at high single digit; and (2) TCM granules at high-teens on more alliances, factories and provinces with reimbursement. Re-iterate BUY with higher SOTP-TP on bigger revenue and lower opex to sales.


CopyRight © 2009-2015 国信证券(香港)经纪有限公司版权所有